PE20050581A1 - Microparticulas que comprenden analogos de somatostatina - Google Patents
Microparticulas que comprenden analogos de somatostatinaInfo
- Publication number
- PE20050581A1 PE20050581A1 PE2004001111A PE2004001111A PE20050581A1 PE 20050581 A1 PE20050581 A1 PE 20050581A1 PE 2004001111 A PE2004001111 A PE 2004001111A PE 2004001111 A PE2004001111 A PE 2004001111A PE 20050581 A1 PE20050581 A1 PE 20050581A1
- Authority
- PE
- Peru
- Prior art keywords
- amino acid
- microparticles
- refers
- polymeric matrix
- lys
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
Abstract
SE REFIERE A MICROPARTICULAS QUE COMPRENDEN UN ANALOGO SOMATOSTATINA QUE COMPRENDE LA SECUENCIA DE AMINOACIDO DE FORMULA I -( D/L) Trp-Lys-X1-X2 DONDE X1 ES UN RADICAL DE FORMULA (a) DONDE R1 ES EL FENILO OPCIONALMENTE SUBSTITUIDO; R2 ES-Z1-CH2-R1,-CH2-CO-O-CH2-R1, DONDE Z1 ES O, S; X2 ES UN AMINOACIDO QUE TIENE UN RESIDUO AROMATICO SOBRE LA CADENA DE LADO LATERAL CO, O UNA UNIDAD DE AMINOACIDO SELECCIONADA A PARTIR DE Dab, Dpr, Dpm, His, (Bzl)Hypro, Tienil-Ala, CORRESPONDIENDO EL RESIDUO Lys DE ESTA SECUENCIA AL RESIDUO Lys9 DE SOMATOSTATINA-14 NATIVA, EN FORMA LIBRE, FORMA DE SAL O EN FORMA PROTEGIDA, ENCAJADA EN UNA MATRIZ POLIMERICA. SE REFIERE A MICROPARTICULAS DONDE LA MATRIZ POLIMERICA COMPRENDE UN POLILACTIDO-CO-GLICOLIDO LINEAL O RAMIFICADO, ADEMAS UN TENSOACTIVO, UN AGENTE QUE INFLUYE EN LA POROSIDAD, UNA SAL BASICA, UN VEHICULO O AGENTE HUMECTANTE SELECCIONADO DE UN POLOXAMERO Y/O UN ESTER DE ACIDO GRASO DE SORBITAN DE POLIOXIETILENO. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE UNA ENFERMEDAD QUE ESTE ASOCIADA CON UN EXCESO DE SECRECION DE HORMONA DE CRECIMIENTO Y/O DE IGF-1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0326602A GB0326602D0 (en) | 2003-11-14 | 2003-11-14 | Organic compounds |
| GB0406241A GB0406241D0 (en) | 2004-03-19 | 2004-03-19 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050581A1 true PE20050581A1 (es) | 2005-09-09 |
Family
ID=34593737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004001111A PE20050581A1 (es) | 2003-11-14 | 2004-11-12 | Microparticulas que comprenden analogos de somatostatina |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7759308B2 (es) |
| EP (1) | EP1686964B9 (es) |
| JP (1) | JP4682145B2 (es) |
| KR (1) | KR101233892B1 (es) |
| AR (1) | AR047310A1 (es) |
| AT (1) | ATE455537T1 (es) |
| AU (1) | AU2004289055C1 (es) |
| BR (1) | BRPI0416227B8 (es) |
| CA (1) | CA2541944C (es) |
| CY (2) | CY1110293T1 (es) |
| DE (1) | DE602004025271D1 (es) |
| DK (1) | DK1686964T3 (es) |
| EC (1) | ECSP066565A (es) |
| ES (1) | ES2339026T3 (es) |
| HK (1) | HK1093682A1 (es) |
| HR (1) | HRP20100190T1 (es) |
| IL (1) | IL175286A (es) |
| IS (1) | IS8480A (es) |
| LU (1) | LU92701I2 (es) |
| MA (1) | MA28155A1 (es) |
| MX (1) | MXPA06005357A (es) |
| MY (1) | MY158342A (es) |
| NO (2) | NO337172B1 (es) |
| NZ (1) | NZ546788A (es) |
| PE (1) | PE20050581A1 (es) |
| PL (1) | PL1686964T3 (es) |
| PT (1) | PT1686964E (es) |
| RU (1) | RU2404749C2 (es) |
| SI (1) | SI1686964T1 (es) |
| TW (1) | TWI295178B (es) |
| WO (1) | WO2005046645A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
| BRPI0620063B8 (pt) * | 2005-12-22 | 2021-05-25 | Novartis Ag | composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração |
| KR100816065B1 (ko) * | 2006-11-27 | 2008-03-24 | 동국제약 주식회사 | 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐 |
| PE20090387A1 (es) * | 2007-05-24 | 2009-04-28 | Novartis Ag | Formulacion de pasireotida |
| AU2009209594A1 (en) * | 2008-01-30 | 2009-08-06 | Novartis Ag | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
| CA2716010C (en) * | 2008-04-03 | 2019-10-01 | Zymogenetics, Inc. | Hemostatic microspheres |
| ES2399651T3 (es) * | 2008-07-08 | 2013-04-02 | Novartis Ag | Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena |
| US20100151033A1 (en) * | 2008-12-15 | 2010-06-17 | Novartis Ag | Octreotide depot formulation with constantly high exposure levels |
| US8815971B2 (en) | 2008-12-22 | 2014-08-26 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
| US8822610B2 (en) | 2008-12-22 | 2014-09-02 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
| US8173750B2 (en) | 2009-04-23 | 2012-05-08 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
| WO2010123574A1 (en) | 2009-04-23 | 2010-10-28 | Atrp Solutions Inc | Star macromolecules for personal and home care |
| US9783628B2 (en) | 2009-04-23 | 2017-10-10 | ATRP Solutions, Inc. | Dual-mechanism thickening agents for hydraulic fracturing fluids |
| US9587064B2 (en) | 2010-12-08 | 2017-03-07 | ATRP Solutions, Inc. | Salt-tolerant star macromolecules |
| WO2013131879A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | New application for pasireotide |
| MX368683B (es) | 2012-08-30 | 2019-10-11 | Pilot Polymer Tech Inc | Agentes espesantes de mecanismo dual para fluidos de fracturación hidráulica. |
| CN105263978B (zh) | 2013-02-04 | 2018-04-17 | Atrp解决方案公司 | 耐盐星形大分子 |
| BR112015022023B1 (pt) | 2013-03-11 | 2022-12-06 | Durect Corporation | Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade |
| TW201605488A (zh) * | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及／或治療多囊腎病之藥物 |
| US10336848B2 (en) | 2014-07-03 | 2019-07-02 | Pilot Polymer Technologies, Inc. | Surfactant-compatible star macromolecules |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| WO1998032423A1 (en) | 1997-01-29 | 1998-07-30 | Takeda Chemical Industries, Ltd. | Sustained-release microspheres, their production and use |
| WO2000004916A1 (en) * | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
| EP1240896A3 (en) * | 1998-07-23 | 2003-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Encapsulation of water soluble peptides |
| ATE226083T1 (de) * | 1998-07-23 | 2002-11-15 | Sod Conseils Rech Applic | Verkapselung wasserlöslicher peptide |
| PL354120A1 (en) | 1999-08-18 | 2003-12-29 | Societe De Conseils De Recherches Et D'applicationsociete De Conseils De Recherches Et D'applications Scientifiques S.A.S.S Scientifiques S.A.S. | Sustained release formulation of a peptide |
| GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| WO2003075892A1 (en) * | 2002-03-13 | 2003-09-18 | Novartis Ag | Pharmaceutical microparticles |
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
-
2004
- 2004-11-09 MY MYPI20044662A patent/MY158342A/en unknown
- 2004-11-11 AR ARP040104157A patent/AR047310A1/es not_active Application Discontinuation
- 2004-11-12 TW TW093134728A patent/TWI295178B/zh active
- 2004-11-12 AU AU2004289055A patent/AU2004289055C1/en active Active
- 2004-11-12 PE PE2004001111A patent/PE20050581A1/es active IP Right Grant
- 2004-11-12 DK DK04797866.3T patent/DK1686964T3/da active
- 2004-11-12 US US10/579,186 patent/US7759308B2/en active Active
- 2004-11-12 PT PT04797866T patent/PT1686964E/pt unknown
- 2004-11-12 NZ NZ546788A patent/NZ546788A/en unknown
- 2004-11-12 SI SI200431378T patent/SI1686964T1/sl unknown
- 2004-11-12 ES ES04797866T patent/ES2339026T3/es active Active
- 2004-11-12 KR KR1020067009270A patent/KR101233892B1/ko active IP Right Grant
- 2004-11-12 BR BRPI0416227A patent/BRPI0416227B8/pt active IP Right Grant
- 2004-11-12 AT AT04797866T patent/ATE455537T1/de active
- 2004-11-12 EP EP04797866A patent/EP1686964B9/en active Active
- 2004-11-12 JP JP2006538808A patent/JP4682145B2/ja active Active
- 2004-11-12 CA CA2541944A patent/CA2541944C/en active Active
- 2004-11-12 WO PCT/EP2004/012870 patent/WO2005046645A1/en active Application Filing
- 2004-11-12 PL PL04797866T patent/PL1686964T3/pl unknown
- 2004-11-12 MX MXPA06005357A patent/MXPA06005357A/es active IP Right Grant
- 2004-11-12 RU RU2006120484/15A patent/RU2404749C2/ru active
- 2004-11-12 DE DE602004025271T patent/DE602004025271D1/de active Active
-
2006
- 2006-04-27 IL IL175286A patent/IL175286A/en active IP Right Grant
- 2006-05-11 MA MA29019A patent/MA28155A1/fr unknown
- 2006-05-12 EC EC2006006565A patent/ECSP066565A/es unknown
- 2006-05-23 IS IS8480A patent/IS8480A/is unknown
- 2006-06-14 NO NO20062777A patent/NO337172B1/no active Protection Beyond IP Right Term
-
2007
- 2007-01-04 HK HK07100155.4A patent/HK1093682A1/xx unknown
-
2010
- 2010-03-09 CY CY20101100222T patent/CY1110293T1/el unknown
- 2010-04-01 HR HR20100190T patent/HRP20100190T1/hr unknown
- 2010-06-08 US US12/796,132 patent/US8188037B2/en active Active
-
2012
- 2012-04-26 US US13/456,681 patent/US20120214749A1/en not_active Abandoned
-
2015
- 2015-03-26 CY CY2015011C patent/CY2015011I2/el unknown
- 2015-04-29 LU LU92701C patent/LU92701I2/xx unknown
-
2016
- 2016-02-02 NO NO2016003C patent/NO2016003I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050581A1 (es) | Microparticulas que comprenden analogos de somatostatina | |
| PE20060713A1 (es) | Polipeptidos moduladores del peptido 1 similar al glucagon humano | |
| KR910007542A (ko) | 폴리펩타이드의 서방형 조성물 | |
| PE20140186A1 (es) | Analogos de glucagon que presentan actividad de receptor de gip | |
| BR0311877A (pt) | Preparações ácidas de insulina com estabilidade aperfeiçoada | |
| PE20090108A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| MX2010004298A (es) | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. | |
| AR023130A1 (es) | Composiciones para promover el crecimiento | |
| PE20121393A1 (es) | Analogo peptidico de oxintomodulina | |
| GT199800085A (es) | Sal tartrato de un dipeptido sustituido. | |
| HUP0303596A2 (hu) | Cinkmentes és cinkben szegény, javított stabilitású inzulinkészítmények | |
| PE20191716A1 (es) | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos | |
| MX2010011329A (es) | Analogos de insulina especificos de isoforma. | |
| AR052030A1 (es) | Nueva composicion para facilitar el parto humano | |
| SMT201300093B (it) | Formulazioni di vwf ricombinante liofilizzate | |
| NZ593190A (en) | Factor viii formulations | |
| SG178797A1 (en) | Oligosaccharide chain added glp-1 peptide | |
| EP2226079A3 (en) | Stem cell derived paracrine factor SFRP2 for use in reducing cell death | |
| MXPA05000412A (es) | Formulacioneks liquidas con una alta concentracion de hormona de crecimiento humana (hgh) que comprenden glicina. | |
| NO20081654L (no) | Stabiliserte GLP-1-analoger | |
| PE20121528A1 (es) | Metodos para administrar agentes hipoglucemiantes de larga duracion | |
| DE60335101D1 (de) | Antimikrobielles polypeptid und nutzung davon | |
| AR063263A1 (es) | Agentes tensioactivos reconstituidos | |
| AR064269A1 (es) | Formulaciones inhalantes de bisfosfonato y metodos para su utilizacion | |
| PE20030974A1 (es) | Agonistas del receptor 2 del factor liberador de la corticotropina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |